glp-1 and parkinson's Are we measuring the wrong primary outcome for drugs for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep GLP-1 Receptor Agonists in Neurodegeneration:

This is the tube that moves urine from your bladder out of your body

Mature erythrocytes have limited synthetic and repair capacities, but to effectively function they must have biochemical pathways that generate enough energy to support cellular function and allow haemoglobin to be maintained in a state that can effectively bind oxygen

Macrophage ferroptosis and endometriosis Ferroptosis releases DAMPs and lipid oxidation products, which affect nonleukocytes and cause inflammatory cell death

They provide important support for mechanistic studies and potential therapeutic strategies for muscle-related diseases

The Body Protection Compound Peptide Known as the Body Protection Compound, BPC-157 peptide has gained attention for its multi-system healing potential

CJC-1295 and ipamorelin work through two different receptor pathways